Cargando…

Optimal hypofractionated conformal radiotherapy for large brain metastases in patients with high risk factors: a single-institutional prospective study

BACKGROUND: A single-institutional prospective study of optimal hypofractionated conformal radiotherapy for large brain metastases with high risk factors was performed based on the risk prediction of radiation-related complications. METHODS: Eighty-eight patients with large brain metastases ≥10 cm(3...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Hiroshi K, Sato, Hiro, Suzuki, Yoshiyuki, Saitoh, Jun-ichi, Noda, Shin-ei, Seto, Ken-ichi, Torikai, Kota, Sakurai, Hideyuki, Nakano, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203932/
https://www.ncbi.nlm.nih.gov/pubmed/25322826
http://dx.doi.org/10.1186/s13014-014-0231-5
_version_ 1782340466283380736
author Inoue, Hiroshi K
Sato, Hiro
Suzuki, Yoshiyuki
Saitoh, Jun-ichi
Noda, Shin-ei
Seto, Ken-ichi
Torikai, Kota
Sakurai, Hideyuki
Nakano, Takashi
author_facet Inoue, Hiroshi K
Sato, Hiro
Suzuki, Yoshiyuki
Saitoh, Jun-ichi
Noda, Shin-ei
Seto, Ken-ichi
Torikai, Kota
Sakurai, Hideyuki
Nakano, Takashi
author_sort Inoue, Hiroshi K
collection PubMed
description BACKGROUND: A single-institutional prospective study of optimal hypofractionated conformal radiotherapy for large brain metastases with high risk factors was performed based on the risk prediction of radiation-related complications. METHODS: Eighty-eight patients with large brain metastases ≥10 cm(3) in critical areas treated from January 2010 to February 2014 using the CyberKnife were evaluated. The optimal dose and number of fractions were determined based on the surrounding brain volume circumscribed with a single dose equivalent (SDE) of 14 Gy (V14) to be less than 7 cm(3) for individual lesions. Univariate and multivariate analyses were conducted. RESULTS: As a result of optimal treatment, 92 tumors ranging from 10 to 74.6 cm(3) (median, 16.2 cm(3)) in volume were treated with a median prescribed isodose of 57% and a median fraction number of five. In order to compare the results according to the tumor volume, the tumors were divided into the following three groups: 1) 10–19.9 cm(3), 2) 20–29.9 cm(3) and 3) ≥30 cm(3). The lesions were treated with a median prescribed isodose of 57%, 56% and 55%, respectively, and the median fraction number was five in all three groups. However, all tumors ≥20 cm(3) were treated with ≥ five fractions. The median SDE of the maximum dose in the three groups was 47.2 Gy, 48.5 Gy and 46.5 Gy, respectively. Local tumor control was obtained in 90.2% of the patients, and the median survival was nine months, with a median follow-up period of seven months (range, 3-41 months). There were no significant differences in the survival rates among the three groups. Six tumors exhibited marginal recurrence 7-36 months after treatment. Ten patients developed symptomatic brain edema or recurrence of pre-existing edema, seven of whom required osmo-steroid therapy. No patients developed radiation necrosis requiring surgical resection. CONCLUSION: Our findings demonstrate that the administration of optimal hypofractionated conformal radiotherapy based on the dose-volume prediction of complications (risk line for hypofractionation), as well as Kjellberg’s necrosis risk line used in single-session radiosurgery, is effective and safe for large brain metastases or other lesions in critical areas.
format Online
Article
Text
id pubmed-4203932
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42039322014-10-22 Optimal hypofractionated conformal radiotherapy for large brain metastases in patients with high risk factors: a single-institutional prospective study Inoue, Hiroshi K Sato, Hiro Suzuki, Yoshiyuki Saitoh, Jun-ichi Noda, Shin-ei Seto, Ken-ichi Torikai, Kota Sakurai, Hideyuki Nakano, Takashi Radiat Oncol Research BACKGROUND: A single-institutional prospective study of optimal hypofractionated conformal radiotherapy for large brain metastases with high risk factors was performed based on the risk prediction of radiation-related complications. METHODS: Eighty-eight patients with large brain metastases ≥10 cm(3) in critical areas treated from January 2010 to February 2014 using the CyberKnife were evaluated. The optimal dose and number of fractions were determined based on the surrounding brain volume circumscribed with a single dose equivalent (SDE) of 14 Gy (V14) to be less than 7 cm(3) for individual lesions. Univariate and multivariate analyses were conducted. RESULTS: As a result of optimal treatment, 92 tumors ranging from 10 to 74.6 cm(3) (median, 16.2 cm(3)) in volume were treated with a median prescribed isodose of 57% and a median fraction number of five. In order to compare the results according to the tumor volume, the tumors were divided into the following three groups: 1) 10–19.9 cm(3), 2) 20–29.9 cm(3) and 3) ≥30 cm(3). The lesions were treated with a median prescribed isodose of 57%, 56% and 55%, respectively, and the median fraction number was five in all three groups. However, all tumors ≥20 cm(3) were treated with ≥ five fractions. The median SDE of the maximum dose in the three groups was 47.2 Gy, 48.5 Gy and 46.5 Gy, respectively. Local tumor control was obtained in 90.2% of the patients, and the median survival was nine months, with a median follow-up period of seven months (range, 3-41 months). There were no significant differences in the survival rates among the three groups. Six tumors exhibited marginal recurrence 7-36 months after treatment. Ten patients developed symptomatic brain edema or recurrence of pre-existing edema, seven of whom required osmo-steroid therapy. No patients developed radiation necrosis requiring surgical resection. CONCLUSION: Our findings demonstrate that the administration of optimal hypofractionated conformal radiotherapy based on the dose-volume prediction of complications (risk line for hypofractionation), as well as Kjellberg’s necrosis risk line used in single-session radiosurgery, is effective and safe for large brain metastases or other lesions in critical areas. BioMed Central 2014-10-17 /pmc/articles/PMC4203932/ /pubmed/25322826 http://dx.doi.org/10.1186/s13014-014-0231-5 Text en © Inoue et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Inoue, Hiroshi K
Sato, Hiro
Suzuki, Yoshiyuki
Saitoh, Jun-ichi
Noda, Shin-ei
Seto, Ken-ichi
Torikai, Kota
Sakurai, Hideyuki
Nakano, Takashi
Optimal hypofractionated conformal radiotherapy for large brain metastases in patients with high risk factors: a single-institutional prospective study
title Optimal hypofractionated conformal radiotherapy for large brain metastases in patients with high risk factors: a single-institutional prospective study
title_full Optimal hypofractionated conformal radiotherapy for large brain metastases in patients with high risk factors: a single-institutional prospective study
title_fullStr Optimal hypofractionated conformal radiotherapy for large brain metastases in patients with high risk factors: a single-institutional prospective study
title_full_unstemmed Optimal hypofractionated conformal radiotherapy for large brain metastases in patients with high risk factors: a single-institutional prospective study
title_short Optimal hypofractionated conformal radiotherapy for large brain metastases in patients with high risk factors: a single-institutional prospective study
title_sort optimal hypofractionated conformal radiotherapy for large brain metastases in patients with high risk factors: a single-institutional prospective study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203932/
https://www.ncbi.nlm.nih.gov/pubmed/25322826
http://dx.doi.org/10.1186/s13014-014-0231-5
work_keys_str_mv AT inouehiroshik optimalhypofractionatedconformalradiotherapyforlargebrainmetastasesinpatientswithhighriskfactorsasingleinstitutionalprospectivestudy
AT satohiro optimalhypofractionatedconformalradiotherapyforlargebrainmetastasesinpatientswithhighriskfactorsasingleinstitutionalprospectivestudy
AT suzukiyoshiyuki optimalhypofractionatedconformalradiotherapyforlargebrainmetastasesinpatientswithhighriskfactorsasingleinstitutionalprospectivestudy
AT saitohjunichi optimalhypofractionatedconformalradiotherapyforlargebrainmetastasesinpatientswithhighriskfactorsasingleinstitutionalprospectivestudy
AT nodashinei optimalhypofractionatedconformalradiotherapyforlargebrainmetastasesinpatientswithhighriskfactorsasingleinstitutionalprospectivestudy
AT setokenichi optimalhypofractionatedconformalradiotherapyforlargebrainmetastasesinpatientswithhighriskfactorsasingleinstitutionalprospectivestudy
AT torikaikota optimalhypofractionatedconformalradiotherapyforlargebrainmetastasesinpatientswithhighriskfactorsasingleinstitutionalprospectivestudy
AT sakuraihideyuki optimalhypofractionatedconformalradiotherapyforlargebrainmetastasesinpatientswithhighriskfactorsasingleinstitutionalprospectivestudy
AT nakanotakashi optimalhypofractionatedconformalradiotherapyforlargebrainmetastasesinpatientswithhighriskfactorsasingleinstitutionalprospectivestudy